|Mr. Antony Mattessich||Pres, CEO & Director||1.04M||N/A||1967|
|Mr. Donald Notman Jr.||Chief Financial Officer||629.17k||N/A||N/A|
|Dr. Peter K. Jarrett Ph.D.||Chief Scientific Officer||N/A||N/A||1957|
|Mr. Philip C. Strassburger||Gen. Counsel||N/A||N/A||1960|
|Mr. William H. Ransone II||VP of Global Sales & Marketing||N/A||N/A||N/A|
|Ms. Tracy Smith||VP of HR||N/A||N/A||N/A|
|Mr. Scott Corning||Sr. VP of Commercial||N/A||N/A||N/A|
|Mr. Christopher G. White||Chief Bus. Officer||N/A||N/A||1962|
|Dr. Rabia Gurses Ozden M.D.||Chief Medical Officer||N/A||N/A||1968|
|Dr. Karen-Leigh Edwards M.B.A., Ph.D.||Sr. VP of Technical Operations||N/A||N/A||N/A|
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Ocular Therapeutix, Inc.’s ISS governance QualityScore as of 1 December 2022 is 9. The pillar scores are Audit: 6; Board: 8; Shareholder rights: 7; Compensation: 10.